S&P 500   5,022.21
DOW   37,753.31
QQQ   425.84
ASML Fires Warning Shot For Tech Investors
Checking in with 5 Bitcoin Stocks Ahead of Bitcoin's Halving
Lululemon’s P/E Is Back to 2017 Levels: Should You Buy the Dip?
Closing prices for crude oil, gold and other commodities
Abbott Laboratories Outlook is Healthy: Buy the Dip
Prologis Stock Leading U.S. Logistics Boom
Johnson & Johnson’s Q1 Checkup: Mixed Results, Optimism Remains
S&P 500   5,022.21
DOW   37,753.31
QQQ   425.84
ASML Fires Warning Shot For Tech Investors
Checking in with 5 Bitcoin Stocks Ahead of Bitcoin's Halving
Lululemon’s P/E Is Back to 2017 Levels: Should You Buy the Dip?
Closing prices for crude oil, gold and other commodities
Abbott Laboratories Outlook is Healthy: Buy the Dip
Prologis Stock Leading U.S. Logistics Boom
Johnson & Johnson’s Q1 Checkup: Mixed Results, Optimism Remains
S&P 500   5,022.21
DOW   37,753.31
QQQ   425.84
ASML Fires Warning Shot For Tech Investors
Checking in with 5 Bitcoin Stocks Ahead of Bitcoin's Halving
Lululemon’s P/E Is Back to 2017 Levels: Should You Buy the Dip?
Closing prices for crude oil, gold and other commodities
Abbott Laboratories Outlook is Healthy: Buy the Dip
Prologis Stock Leading U.S. Logistics Boom
Johnson & Johnson’s Q1 Checkup: Mixed Results, Optimism Remains
S&P 500   5,022.21
DOW   37,753.31
QQQ   425.84
ASML Fires Warning Shot For Tech Investors
Checking in with 5 Bitcoin Stocks Ahead of Bitcoin's Halving
Lululemon’s P/E Is Back to 2017 Levels: Should You Buy the Dip?
Closing prices for crude oil, gold and other commodities
Abbott Laboratories Outlook is Healthy: Buy the Dip
Prologis Stock Leading U.S. Logistics Boom
Johnson & Johnson’s Q1 Checkup: Mixed Results, Optimism Remains
NASDAQ:ELDN

Eledon Pharmaceuticals (ELDN) Stock Price, News & Analysis

$1.57
-0.03 (-1.88%)
(As of 04/17/2024 ET)
Today's Range
$1.56
$1.68
50-Day Range
$1.54
$2.13
52-Week Range
$1.07
$2.95
Volume
12,526 shs
Average Volume
75,488 shs
Market Capitalization
$38.96 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$10.67

Eledon Pharmaceuticals MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
579.4% Upside
$10.67 Price Target
Short Interest
Healthy
0.43% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($1.38) to ($0.88) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.42 out of 5 stars

Medical Sector

384th out of 913 stocks

Pharmaceutical Preparations Industry

158th out of 397 stocks

ELDN stock logo

About Eledon Pharmaceuticals Stock (NASDAQ:ELDN)

Eledon Pharmaceuticals, Inc. operates as a clinical stage biotechnology company. The company uses its immunology expertise in targeting the CD40 Ligand (CD40L, also called CD154) pathway to develop therapies to protect transplanted organs and prevent rejection, and to treat amyotrophic lateral sclerosis (ALS). The company's lead compound in development is tegoprubart, an anti-CD40L antibody with high affinity for CD40 Ligand, a biological target with therapeutic potential. It has a collaboration agreement with eGenesis, Inc. The company was formerly known as Novus Therapeutics, Inc. and changed its name to Eledon Pharmaceuticals, Inc. in January 2021. Eledon Pharmaceuticals, Inc. is headquartered in Irvine, California.

ELDN Stock Price History

ELDN Stock News Headlines

Could Bitcoin Literally FORCE This Crypto To Rocket Up?
Recently, Bitcoin smashed through its previous record high to hit $72,720. It’s made many, many people very rich. But one cryptocurrency expert and investing millionaire is declaring…
Could Bitcoin Literally FORCE This Crypto To Rocket Up?
Recently, Bitcoin smashed through its previous record high to hit $72,720. It’s made many, many people very rich. But one cryptocurrency expert and investing millionaire is declaring…
Eledon Pharmaceuticals, Inc. (ELDN)
Eledon Pharmaceuticals Inc ELDN
Eledon Pharmaceuticals Appoints Eliezer Katz As Chief Medical Officer
See More Headlines
Receive ELDN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Eledon Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
3/28/2024
Today
4/17/2024
Next Earnings (Estimated)
5/09/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:ELDN
Fax
N/A
Employees
17
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$10.67
High Stock Price Target
$13.00
Low Stock Price Target
$9.00
Potential Upside/Downside
+579.4%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
3 Analysts

Profitability

Net Income
$-40,330,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$3.45 per share

Miscellaneous

Free Float
19,999,000
Market Cap
$38.96 million
Optionable
Optionable
Beta
0.87
13 Stocks Institutional Investors Won't Stop Buying Cover

Which stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.

Get This Free Report

Key Executives

  • Dr. David-Alexandre C. Gros M.D.Dr. David-Alexandre C. Gros M.D. (Age 52)
    Ph.D., CEO & Non Independent Director
    Comp: $807.96k
  • Dr. Steven N. Perrin Ph.D. (Age 58)
    President, Chief Scientific Officer & Non Independent Director
    Comp: $603.9k
  • Mr. Paul Sean Little (Age 59)
    CFO & Principal Accounting Officer
    Comp: $611.71k
  • Mr. John Herberger
    Vice President of Technical Operations
  • Mr. Bryan E. Smith J.D. (Age 44)
    General Counsel, Corporate Secretary & Chief Compliance Officer
    Comp: $377.14k
  • Dr. David Hovland Ph.D.
    Chief Regulatory Officer
  • Dr. Eliezer Katz F.A.C.S.
    FACS, M.D., Chief Medical Officer

ELDN Stock Analysis - Frequently Asked Questions

Should I buy or sell Eledon Pharmaceuticals stock right now?

3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Eledon Pharmaceuticals in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" ELDN shares.
View ELDN analyst ratings
or view top-rated stocks.

What is Eledon Pharmaceuticals' stock price target for 2024?

3 brokerages have issued twelve-month price objectives for Eledon Pharmaceuticals' stock. Their ELDN share price targets range from $9.00 to $13.00. On average, they anticipate the company's stock price to reach $10.67 in the next year. This suggests a possible upside of 579.4% from the stock's current price.
View analysts price targets for ELDN
or view top-rated stocks among Wall Street analysts.

How have ELDN shares performed in 2024?

Eledon Pharmaceuticals' stock was trading at $1.80 at the start of the year. Since then, ELDN shares have decreased by 12.8% and is now trading at $1.57.
View the best growth stocks for 2024 here
.

Are investors shorting Eledon Pharmaceuticals?

Eledon Pharmaceuticals saw a increase in short interest during the month of March. As of March 31st, there was short interest totaling 106,900 shares, an increase of 193.7% from the March 15th total of 36,400 shares. Based on an average trading volume of 78,000 shares, the days-to-cover ratio is presently 1.4 days.
View Eledon Pharmaceuticals' Short Interest
.

When is Eledon Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024.
View our ELDN earnings forecast
.

How were Eledon Pharmaceuticals' earnings last quarter?

Eledon Pharmaceuticals, Inc. (NASDAQ:ELDN) posted its quarterly earnings data on Thursday, March, 28th. The company reported ($0.29) earnings per share for the quarter, beating analysts' consensus estimates of ($0.38) by $0.09.

How do I buy shares of Eledon Pharmaceuticals?

Shares of ELDN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:ELDN) was last updated on 4/18/2024 by MarketBeat.com Staff

From Our Partners